ArticleAntimicrobial agents and chemotherapy2016
Targeting Fibronectin To Disrupt In Vivo Candida albicans Biofilms.
Article in Antimicrobial agents and chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 22 citations in OpenAlex.
- Fibronectin recognition by the emerging multidrug-resistant opportunistic fungal pathogen Candida haemulonii.Folia microbiologica · 2025Article
- Characteristics and Outcome of Vascular Graft Infections: A Risk Factor and Survival Analysis.Open forum infectious diseases · 2024Article
- Biofilm inhibition/eradication: exploring strategies and confronting challenges in combatting biofilm.Archives of microbiology · 2024Review
- Combating Bacterial Biofilms: Current and Emerging Antibiofilm Strategies for Treating Persistent Infections.Antibiotics (Basel, Switzerland) · 2023Review
- A global bibliometric and visualized analysis of bacterial biofilm eradication from 2012 to 2022.Frontiers in microbiology · 2023Review
- Filament Negative RegulatorJournal of fungi (Basel, Switzerland) · 2022Article
- Targeting Biofilms Therapy: Current Research Strategies and Development Hurdles.Microorganisms · 2020Review
- Understanding Biofilms and Novel Approaches to the Diagnosis, Prevention, and Treatment of Medical Device-Associated Infections.Infectious disease clinics of North America · 2018Review
- Targeting microbial biofilms: current and prospective therapeutic strategies.Nature reviews. Microbiology · 2017Review
- Fungal Biofilms: Inside Out.Microbiology spectrum · 2017Review
- Fungal Super Glue: The Biofilm Matrix and Its Composition, Assembly, and Functions.PLoS pathogens · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
New drug targets are of great interest for the treatment of fungal biofilms, which are routinely resistant to antifungal therapies. We theorized that the interaction of Candida albicans with matricellular host proteins would provide a novel target. Here, we show that an inhibitory protein (FUD) targeting Candida-fibronectin interactions disrupts biofilm formation in vitro and in vivo in a rat venous catheter model. The peptide appears to act by blocking the surface adhesion of Candida, halting biofilm formation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.